AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier
Le stock est insuffisant. unités ont été rajoutées au panier
En rupture de stock
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
photos non contractuelles
Product description: alpha-1-antichymotrypsin (ACT) is a glycoprotein with a molecular weight of 55~68 kDa and 25% by weight of various sugars, whose heterogeneity results in variation of molecular weight. It inhibits chymotrypsin-like proteinases in vivo and has cytotoxic killer-cell activity in vitro. The protein also has a role as an acute-phase protein and is active in the control of immunologic and inflammatory processes, and as a tumor marker. Plasma ACT levels might increase rapidly more than 5-fold during an acute phase reaction, ACT has been shown to promote Abeta polymerization in vitro and in vivo, and levels of ACT protein in plasma and cerebrospinal fluid from Alzheimer's patients have been found to correlate with progression of dementia. Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.
Alternate Names/Synonyms: AACT; GIG24; SERPINA3
Product Type: Monoclonal Antibody
Isotype: Mouse IgG1 kappa
Immunogen: Protein purified from human plasma.
Applications: IHC, WB
Species Crossreactivity: Human
Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Long Term Storage: -20°C
Shipping: BLUE ICE
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.
Veuillez saisir les champs obligatoires!